



CLINICAL INFORMATION

FAQ, Phase III Safety and Efficacy Data, Drug Facts, Mechanism of Action Video

SEE MORE



READY-TO-USE RESOURCES

How to order, coupon tearpads, request samples, educational videos, downloadable social media posts and digital banners

SEE MORE



REAL EXPERIENCES

Read and see how doctors are recommending LUMIFY for their patients

SEE MORE



LUMIFY REDNESS RELIEVER EYE DROPS

A redness reliever like no other

LUMIFY (brimonidine tartrate ophthalmic solution 0.025%) is the first and only over-the-counter (OTC) eye drop developed with low-dose brimonidine tartrate for the treatment of ocular redness due to minor eye irritations.

- Fast acting and long lasting efficacy
- A unique method of action for reducing redness[†]
- Low risk for tachyphylaxis or rebound hyperemia when used as directed


 $\label{thm:prop} $$ ^{\perp}$ UMIFY is a selective $\alpha 2-AR$ against that selectively constricts the venule while maintaining availability of oxygen to surrounding tissue.$



SEE HOW LUMIFY WORKS DIFFERENTLY

LUMIFY selectively constricts the venule, alleviating the potential decrease of blood and oxygen flow to surrounding tissue.

WATCH THE VIDEO >



HOW LUMIFY COMPARES



Other OTC redness relievers

(α1 or α1/α2-AR agonist)

Commonly associated with rebound redness and tachyphylaxis

Non-selective vasoconstrictors act on the arteriole, decreasing blood and oxygen flow to surrounding tissue.



LUMIFY with low dose brimonidine tartrate


(Selective α2-AR agonist)

No tachyphylaxis and virtually no rebound redness in clinical trials when used as directed

LUMIFY selectively constricts the venule, alleviating the potential decrease of blood and oxygen flow to surrounding tissue.


SEE THE RESULTS

Real results from real people, no retouching.*









• 0 0 0



8/15/2022

